drugset / Trial / NCT00501111

Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease

NCT00501111

Phase 2 Completed 659 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to demonstrate that AZD3480 improves cognition in patients with mild or moderate Alzheimer's disease, to assess the safety and tolerability of ZAD3480 and to define the optimal dose(s) to be used in future trials.

Timeline

Start
2007-07
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Donepezil Small molecule Oral
Subject ispronicline Small molecule Oral

Indications